NRG Oncology SPPORT analysis highlights potential role of genetic testing in identifying p
Audio narration · Coming soon
Analysis of the NRG-RTOG 0534 SPPORT trial suggests genetic testing using the PAM50 classifier can identify prostate cancer patients who may benefit most from hormone therapy.
Why this matters
PRISM scored this story 75/100 for interest.
Originally published by gnews